

Special Issue

Novel Approaches to Cancer Immuno-Therapeutics

Message from the Guest Editors

Cancer immunotherapy uses a person's immune system to invoke its in-built potential to kill cancer cells. Over the years, checkpoint blockade immunotherapy has revolutionized the field of cancer. Several checkpoint blockade inhibitors to molecules such as PD-1 (programmed cell death 1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) have been approved by the FDA for the treatment of various cancer types. However, many of these treatments have still not reached to the majority of patients, and not all types of cancers respond to them. Additionally, some patients develop immunotherapy-associated adverse events. All of this means that there is still a lot of room for improvement when it comes to these therapies, but also huge potential. This Special Issue is focused on recent novel developments in cancer immunotherapeutics, development of new approaches to identify novel targets of immunotherapy, and recent developments in combinatorial approaches.

Guest Editors

Dr. Youg Raj Thaker

School of Life Sciences, University of Essex, Colchester, UK

Prof. Dr. Frank Schildberg

Department for Orthopedics and Trauma Surgery, University Hospital Bonn, 53127 Bonn, Germany

Deadline for manuscript submissions

closed (31 October 2021)



Biology

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.4
Indexed in PubMed



mdpi.com/si/59035

Biology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biology@mdpi.com

[mdpi.com/journal/
biology](https://mdpi.com/journal/biology)





Biology

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.4
Indexed in PubMed



[mdpi.com/journal/
biology](https://mdpi.com/journal/biology)



About the Journal

Message from the Editorial Board

A major strength of biological science is the diversity of approaches that biological scientists apply to their research problems. *Biology* reflects this diversity and brings together studies employing the varied experimental and theoretical approaches that are fueling biological discovery. *Biology*, the journal, is a fully peer-reviewed publication with a rapid and economical route to open access publication and is listed on PubMed. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

Editors-in-Chief

Prof. Dr. Jukka Finne

Research Programme in Molecular and Integrative Biosciences, Faculty of Biological and Environmental Sciences, University of Helsinki, P.O. Box 56, FI-00014 Helsinki, Finland

Prof. Dr. Andrés Moya

Integrative Systems Biology Institute, University of Valencia and CSIC, 46980 Valencia, Spain

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biology) / CiteScore - Q1 (General Agricultural and Biological Sciences)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.4 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).